Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gynion LLC is currently handling 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, which indicates that the company is managing two separate examination processes simultaneously. The presence of 2 pending actions suggests a focused effort to advance its patent applications through the review stage. This distribution allows for independent examination paths for each of the company's active matters.
The company's pending matters are located across 2 distinct art units, which may reflect differences in the specific technical focus of each application. MOU, LIYUAN is identified as the busiest examiner, currently overseeing 1 pending office action. Since this examiner is responsible for 1 of the 2 pending matters, they handle half of the company's active workload. This distribution means that the prosecution strategy must be adapted to the specific feedback and examination styles of two different officials in two separate art units to achieve success.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270900 | SYSTEM AND METHOD FOR DELIVERING THERAPEUTIC AGENTS TO THE UTERINE CAVITY | MOU, LIYUAN | 15d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270900 | SYSTEM AND METHOD FOR DELIVERING THERAPEUTIC AGENTS TO THE UTERINE CAVITY | MOU, LIYUAN | 1628 | §103§112DP | Final Rejection | 15d | Pending | Jul 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGynion LLC has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Liyuan Mou has the most, with 1 of Gynion LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.